Clinical Trials Logo

Filter by:
NCT ID: NCT03954366 Recruiting - Neoplasms Clinical Trials

Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

Start date: May 8, 2019
Phase: Phase 1
Study type: Interventional

This study will investigate the drug-drug interactions (DDIs) between rucaparib and oral rosuvastatin (Arm A), and between rucaparib and oral ethinylestradiol and levonorgestrel (Arm B), with rucaparib as a perpetrator.

NCT ID: NCT03951805 Recruiting - Clinical trials for Diabetes Mellitus, Type 2

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

Start date: May 9, 2019
Phase: Phase 2
Study type: Interventional

This study compares insulin 287 (a possible new medicine) to insulin glargine (a medicine doctors can already prescribe) in people with type 2 diabetes. Different ways of changing the dose of insulin 287 are also compared. This is done to find the best way to change the dose of insulin 287. Participants will either get insulin 287 that they will have to inject once a week or insulin glargine that participants will have to inject once a day. Which treatment participants get is decided by chance. The study will last for about 5 months (23 weeks). Participants will have 14 clinic visits and 6 phone calls with the study doctor. At 3 of the clinic visits participants will be asked not to eat or drink anything (except for water) in the last 8 hours before the visit. During the study, the study doctor will ask participants to: - measure blood sugar every day with a blood sugar meter using a finger prick. - write down different information in a diary daily and return this to the study doctor. - wear a medical device (sensor) that measure blood sugar all the time for 18 weeks (about 4 months) during the study. Women cannot take part if pregnant, breastfeeding or plan to become pregnant during the study period.

NCT ID: NCT03950830 Not yet recruiting - Germ Cell Tumor Clinical Trials

Disulfiram and Cisplatin in Refractory TGCTs.

Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

Non-randomized, open-label, single center trial to assess efficacy (as measured by overall response rate (ORR) by RECIST 1.1 of disulfiram and cisplatin in patients with multiple relapsed/refractory germ cell tumors (GCTs).

NCT ID: NCT03927144 Not yet recruiting - Episodic Migraine Clinical Trials

Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients

Start date: May 20, 2019
Phase: Phase 4
Study type: Interventional

The primary objective is to demonstrate the superiority of subcutaneous erenumab compared to oral prophylactic(s) on sustained benefit defined as % subjects completing one-year on the randomized treatment and achieving at least a 50% reduction from baseline in monthly migraine days at month 12.

NCT ID: NCT03916666 Recruiting - Clinical trials for Chronic Low Back Pain

Chronic Low Back Pain - Epiduroscopy Treatment

Start date: April 5, 2019
Study type: Observational

Retrospective analysis of patients with low back pain after epiduroscopic procedure

NCT ID: NCT03915964 Not yet recruiting - Clinical trials for Rheumatoid Arthritis

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Start date: April 22, 2019
Phase: Phase 4
Study type: Interventional

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

NCT ID: NCT03915301 Recruiting - Pain Reliefe Clinical Trials

Effective Postoperative Pain Treatment After Sternotomy. Comparison of the Erector Spinae Plane Block vs Conventional Opioid Treatment

Start date: May 1, 2019
Study type: Observational [Patient Registry]

Comparison of effect between Erector Spinae plane block and conventional opioid treatment after cardiac surgery

NCT ID: NCT03909204 Not yet recruiting - Constipation Clinical Trials

LAPEC for the Treatment of Severe Constipation

Start date: May 1, 2019
Phase: N/A
Study type: Interventional

Effective treatment for constipation is a real clinical challenge especially in patients with severe symptoms. Dietary measures (bulking agents) and drugs (laxatives, stool softeners, suppositories and enemas etc.) have limited efficacy in severe cases. If conservative measures do not help, surgical therapies might be considered. Subsequently, antegrade enemas through percutaneous colonic catheter were introduced as a less invasive option for treating severe constipation. The cecostomy has been performed laparoscopically, percutaneously, and with the laparoscopic-assisted percutaneous endoscopic cecostomy (LAPEC) technique. This approach allows patients to deliver osmotic agents to the right colon.The procedure has been demonstrated to be safe and effective in young adults and pediatrics. To date, there are only few studies evaluating the safety and efficacy of the LAPEC procedure in adults and all have retrospective profile. The aim of this prospective study is to compare short and long-term efficacy and safety of LAPEC in patients with severe constipation. Symptoms of defecation will be the main outcome criteria.

NCT ID: NCT03905642 Completed - Cystic Fibrosis Clinical Trials

Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension Phase

Start date: January 8, 2009
Phase: Phase 2
Study type: Interventional

A major factor in the respiratory health of cystic fibrosis (CF) patients is acquisition of chronic Pseudomonas (P.) aeruginosa infections. The infection rate with P. aeruginosa increases with age and by age 18 years, 80% of patients with CF in the U.S. are infected. Liposomal amikacin for inhalation (LAI; Arikayce™) is a sterile aqueous liposomal suspension consisting of amikacin sulfate encapsulated in liposomes. This formulation of amikacin maximizes the achievable dose and delivery to the lungs of infected patients when delivered via a nebulizer. Because liposome particles are small enough to penetrate and diffuse through sputum into the bacterial biofilm, they deposit drug close to the bacterial colonies (Meers, et al., 2008) (Clancy, et al., 2013), thus improving the bioavailability of amikacin at the infection site. The clinically achievable doses of amikacin in the LAI formulation can effectively increase the half-life of the drug in the lungs, and decrease the potential for systemic toxicity. LAI offers several advantages over current therapies in treating patients with CF with chronic infection caused by P. aeruginosa.

NCT ID: NCT03890809 Recruiting - Healthy Volunteers Clinical Trials

An Investigational Study of BMS-986165 in Participants With Normal Liver Function and Participants With Mild, Moderate and Severe Liver Damage

Start date: February 25, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate BMS-986165 in participants with different levels of liver function.